董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Vered Caplan | 女 | Chief Executive Officer, Chairperson of the Board | 54 | 397.68万美元 | 未持股 | 2022-10-19 |
| Guy Yachin | 男 | Director | 54 | 13.45万美元 | 未持股 | 2022-10-19 |
| Yaron Adler | 男 | Director | 52 | 8.64万美元 | 未持股 | 2022-10-19 |
| Ashish Nanda | 男 | Director | 56 | 9.29万美元 | 未持股 | 2022-10-19 |
| Mario Philips | 男 | Director | 53 | 7.42万美元 | 未持股 | 2022-10-19 |
| David Sidransky | 男 | Director | 62 | 14.10万美元 | 未持股 | 2022-10-19 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Vered Caplan | 女 | Chief Executive Officer, Chairperson of the Board | 54 | 397.68万美元 | 未持股 | 2022-10-19 |
| Neil Reithinger | 男 | Chief Financial Officer, Secretary and Treasurer | 52 | 21.59万美元 | 未持股 | 2022-10-19 |
| Efrat Assa Kunik | 女 | Chief Development Officer | 48 | 未披露 | 未持股 | 2022-10-19 |
董事简历
中英对照 | 中文 | 英文- Vered Caplan
-
Vered Caplan自2014年8月14日以来一直担任我们的首席执行官兼董事会主席，在此之前，她从2013年12月23日开始担任临时总裁兼首席执行官。她于2012年2月加入我们的董事会。Caplan女士拥有硕士学位。Tel Aviv University生物医学工程专业信号处理；Tel Aviv University商业开发专业工程师管理；Technion-Israel Institute of Technology机械工程专业软件和CAD系统。
Vered Caplan has served as Orgenesis Inc.'s Chief Executive Officer "CEO" and Chairperson of the Board of Directors since August 14 2014 prior to which she served as Interim President and CEO commencing on December 23 2013. She joined Orgenesis Inc.'s Board of Directors in February 2012. Ms. Caplan holds a M.Sc. in biomedical engineering from Tel Aviv University specializing in signal processing; management for engineers from Tel Aviv University specializing in business development; and a B.Sc. in mechanical engineering from the Technion- Israel Institute of Technology specialized in software and cad systems. - Vered Caplan自2014年8月14日以来一直担任我们的首席执行官兼董事会主席，在此之前，她从2013年12月23日开始担任临时总裁兼首席执行官。她于2012年2月加入我们的董事会。Caplan女士拥有硕士学位。Tel Aviv University生物医学工程专业信号处理；Tel Aviv University商业开发专业工程师管理；Technion-Israel Institute of Technology机械工程专业软件和CAD系统。
- Vered Caplan has served as Orgenesis Inc.'s Chief Executive Officer "CEO" and Chairperson of the Board of Directors since August 14 2014 prior to which she served as Interim President and CEO commencing on December 23 2013. She joined Orgenesis Inc.'s Board of Directors in February 2012. Ms. Caplan holds a M.Sc. in biomedical engineering from Tel Aviv University specializing in signal processing; management for engineers from Tel Aviv University specializing in business development; and a B.Sc. in mechanical engineering from the Technion- Israel Institute of Technology specialized in software and cad systems.
- Guy Yachin
-
Guy Yachin自2012年4月2日被任命以来一直担任董事。Yachin先生从2013年4月开始担任Serpin Pharma的总裁兼首席执行官，该公司是一家位于弗吉尼亚州的临床阶段的公司，专注于抗炎药物的开发。Yachin先生从2010年开始担任Oasis Management的首席执行官，这是一家总部位于马里兰州的咨询公司。Yachin先生是Nasvax有限公司（Nasvax Ltd.）的首席执行官，该公司专注于改进免疫疗法和疫苗的开发。在加入Nasvax之前，Yachin先生担任Multigene Vascular Systems Ltd.的首席执行官，该公司是一家专注于血管疾病的细胞治疗公司，领导该公司通过在美国和以色列的临床研究，财务回合以及与Teva Pharmaceuticals Industries Ltd.的Keystone战略协议。他曾担任Chiasma公司（生物技术公司，专注于大分子药物的口服递送）的首席执行官兼创始人，在那里他曾建立公司在以色列和美国的业务，完成了许多财务回合，并指导公司的战略和运营6年以上。此前，他曾担任Naiot Technology Center Ltd.的首席执行官，并为Remon Medical Technologies Ltd.、EnzymotecLtd.和NanoPass Technologies Ltd.等十几家生物医学初创公司提供种子基金和指导。他持有学士学位。the Technion-Israel Institute of Technology工业工程和管理工商管理硕士学位。Yachin先生于2014年3月至2016年4月担任Peak Pharmaceuticals，Inc.的董事会成员。
Guy Yachin has served as a director since his appointment on April 2 2012. Mr. Yachin has served as the President and CEO of Serpin Pharma, a clinical stage Virginia-based company focused on the development of anti-inflammatory drugs, since April 2013. Mr. Yachin is the CEO of Oasis Management, a Maryland-based consulting company, since 2010. Mr. Yachin is the CEO of NasVax Ltd., a company focused on the development of improved immunotherapeutics and vaccines. Prior to joining NasVax, Mr. Yachin served as CEO of MultiGene Vascular Systems Ltd., a cell therapy company focused on blood vessels disorders, leading the company through clinical studies in the U.S. and Israel, financial rounds, and a keystone strategic agreement with Teva Pharmaceuticals Industries Ltd. He was CEO and founder of Chiasma Inc., a biotechnology company focused on the oral delivery of macromolecule drugs, where he built the company’s presence in Israel and the U.S., concluded numerous financial rounds, and guided the company’s strategy and operation for over six years. Earlier, he was CEO of Naiot Technological Center Ltd., and provided seed funding and guidance to more than a dozen biomedical startups such as Remon Medical Technologies Ltd., Enzymotec Ltd. and NanoPass Technologies Ltd. He holds a BSc. in Industrial Engineering and Management and an MBA from the Technion - Israel Institute of Technology. Mr. Yachin served on the board of Peak Pharmaceuticals, Inc. from March 2014 to April 2016. - Guy Yachin自2012年4月2日被任命以来一直担任董事。Yachin先生从2013年4月开始担任Serpin Pharma的总裁兼首席执行官，该公司是一家位于弗吉尼亚州的临床阶段的公司，专注于抗炎药物的开发。Yachin先生从2010年开始担任Oasis Management的首席执行官，这是一家总部位于马里兰州的咨询公司。Yachin先生是Nasvax有限公司（Nasvax Ltd.）的首席执行官，该公司专注于改进免疫疗法和疫苗的开发。在加入Nasvax之前，Yachin先生担任Multigene Vascular Systems Ltd.的首席执行官，该公司是一家专注于血管疾病的细胞治疗公司，领导该公司通过在美国和以色列的临床研究，财务回合以及与Teva Pharmaceuticals Industries Ltd.的Keystone战略协议。他曾担任Chiasma公司（生物技术公司，专注于大分子药物的口服递送）的首席执行官兼创始人，在那里他曾建立公司在以色列和美国的业务，完成了许多财务回合，并指导公司的战略和运营6年以上。此前，他曾担任Naiot Technology Center Ltd.的首席执行官，并为Remon Medical Technologies Ltd.、EnzymotecLtd.和NanoPass Technologies Ltd.等十几家生物医学初创公司提供种子基金和指导。他持有学士学位。the Technion-Israel Institute of Technology工业工程和管理工商管理硕士学位。Yachin先生于2014年3月至2016年4月担任Peak Pharmaceuticals，Inc.的董事会成员。
- Guy Yachin has served as a director since his appointment on April 2 2012. Mr. Yachin has served as the President and CEO of Serpin Pharma, a clinical stage Virginia-based company focused on the development of anti-inflammatory drugs, since April 2013. Mr. Yachin is the CEO of Oasis Management, a Maryland-based consulting company, since 2010. Mr. Yachin is the CEO of NasVax Ltd., a company focused on the development of improved immunotherapeutics and vaccines. Prior to joining NasVax, Mr. Yachin served as CEO of MultiGene Vascular Systems Ltd., a cell therapy company focused on blood vessels disorders, leading the company through clinical studies in the U.S. and Israel, financial rounds, and a keystone strategic agreement with Teva Pharmaceuticals Industries Ltd. He was CEO and founder of Chiasma Inc., a biotechnology company focused on the oral delivery of macromolecule drugs, where he built the company’s presence in Israel and the U.S., concluded numerous financial rounds, and guided the company’s strategy and operation for over six years. Earlier, he was CEO of Naiot Technological Center Ltd., and provided seed funding and guidance to more than a dozen biomedical startups such as Remon Medical Technologies Ltd., Enzymotec Ltd. and NanoPass Technologies Ltd. He holds a BSc. in Industrial Engineering and Management and an MBA from the Technion - Israel Institute of Technology. Mr. Yachin served on the board of Peak Pharmaceuticals, Inc. from March 2014 to April 2016.
- Yaron Adler
-
Yaron Adler自2012年4月17日被任命以来一直担任董事。Adler先生自2014年4月起担任股权众筹平台ExitValley Ltd.的董事长，并担任初创企业孵化器We Group Ltd.的联合创始人。Adler先生于1999年联合创立了IncrediMail Ltd.，并担任其首席执行官至2008年，总裁至2009年。在创立IncrediMail之前的1999年，Adler先生就互联网产品、服务和技术咨询了以色列创业公司。Adler先生从1997年到1999年担任Tecnomatix Technologies Ltd.的产品经理，从1994年到1997年担任软件工程师，该公司是一家软件公司，为复杂的自动化生产线开发和营销生产工程解决方案，填补了产品设计和生产之间的差距，并于2005年4月被UGS Corp.收购。1993年，Adler先生在英特尔以色列有限公司（Intel Israel Ltd.）担任软件工程师。他在特拉维夫大学（Tel Aviv University）获得计算机科学和经济学学士学位。
Yaron Adler has served as a director since his appointment on April 17 2012. Mr. Adler is the chairman of ExitValley Ltd., an equity-based crowdfunding platform, since April 2014 and the co-founder of a startup incubator, We Group Ltd. In 1999 Mr. Adler co-founded IncrediMail Ltd. and served as its CEO until 2008 and President until 2009. In 1999 prior to founding IncrediMail, Mr. Adler consulted Israeli startup companies regarding Internet products, services and technologies. Mr. Adler served as a product manager from 1997 to 1999 and as a software engineer from 1994 to 1997 at Tecnomatix Technologies Ltd., a software company that develops and markets production engineering solutions to complex automated manufacturing lines that fill the gap between product design and production, and which was acquired by UGS Corp. in April 2005. In 1993 Mr. Adler held a software engineer position at Intel Israel Ltd. He has a B.A. in computer sciences and economics from Tel Aviv University. - Yaron Adler自2012年4月17日被任命以来一直担任董事。Adler先生自2014年4月起担任股权众筹平台ExitValley Ltd.的董事长，并担任初创企业孵化器We Group Ltd.的联合创始人。Adler先生于1999年联合创立了IncrediMail Ltd.，并担任其首席执行官至2008年，总裁至2009年。在创立IncrediMail之前的1999年，Adler先生就互联网产品、服务和技术咨询了以色列创业公司。Adler先生从1997年到1999年担任Tecnomatix Technologies Ltd.的产品经理，从1994年到1997年担任软件工程师，该公司是一家软件公司，为复杂的自动化生产线开发和营销生产工程解决方案，填补了产品设计和生产之间的差距，并于2005年4月被UGS Corp.收购。1993年，Adler先生在英特尔以色列有限公司（Intel Israel Ltd.）担任软件工程师。他在特拉维夫大学（Tel Aviv University）获得计算机科学和经济学学士学位。
- Yaron Adler has served as a director since his appointment on April 17 2012. Mr. Adler is the chairman of ExitValley Ltd., an equity-based crowdfunding platform, since April 2014 and the co-founder of a startup incubator, We Group Ltd. In 1999 Mr. Adler co-founded IncrediMail Ltd. and served as its CEO until 2008 and President until 2009. In 1999 prior to founding IncrediMail, Mr. Adler consulted Israeli startup companies regarding Internet products, services and technologies. Mr. Adler served as a product manager from 1997 to 1999 and as a software engineer from 1994 to 1997 at Tecnomatix Technologies Ltd., a software company that develops and markets production engineering solutions to complex automated manufacturing lines that fill the gap between product design and production, and which was acquired by UGS Corp. in April 2005. In 1993 Mr. Adler held a software engineer position at Intel Israel Ltd. He has a B.A. in computer sciences and economics from Tel Aviv University.
- Ashish Nanda
-
Ashish Nanda自2017年2月22日获委任以来一直担任董事。自1998年以来，Nanda先生一直担任Innovations Group的董事总经理，Innovations Group是金融部门最大的外包公司之一，拥有近14000名员工，在各个金融部门工作。自1992年以来，Nanda先生担任Capstone Insurance Brokers LLC的管理合伙人，自2009年以来，他一直担任Dive Tech Marine Engineering Services L.L.C.的管理合伙人（从1991年到1994年），在阿联酋银行集团（Emirates Banking Group）担任助理经理，负责与阿拉伯联合酋长国国民拥有的企业建立关系。和外籍人士，以建立银行限额，也在那里他管理260亿美元的投资组合。Nanda先生持有印度特许会计师协会（Institute of Chartered Accountants）的特许会计。
Ashish Nanda has served as a director since his appointment on February 22 2017. Since 1998 Mr. Nanda has been the Managing Director of Innovations Group, one of the largest outsourcing companies in the financial sector that employs close to 14000 people working across various financial sectors. Since 1992 Mr. Nanda has served as the Managing Partner of Capstone Insurance Brokers LLC and, since 2009 has served as Managing Partner of Dive Tech Marine Engineering Services L.L.C. From 1991 to 1994 Mr. Nanda held the position of Asst. Manager Corporate Banking at Emirates Banking Group where he was involved in establishing relationships with business houses owned by United Arab Emirates nationals and expatriates in order to set up banking limits and also where he managed portfolios of $26 billion. Mr. Nanda holds a Chartered Accountancy from the Institute of Chartered Accountants from India. - Ashish Nanda自2017年2月22日获委任以来一直担任董事。自1998年以来，Nanda先生一直担任Innovations Group的董事总经理，Innovations Group是金融部门最大的外包公司之一，拥有近14000名员工，在各个金融部门工作。自1992年以来，Nanda先生担任Capstone Insurance Brokers LLC的管理合伙人，自2009年以来，他一直担任Dive Tech Marine Engineering Services L.L.C.的管理合伙人（从1991年到1994年），在阿联酋银行集团（Emirates Banking Group）担任助理经理，负责与阿拉伯联合酋长国国民拥有的企业建立关系。和外籍人士，以建立银行限额，也在那里他管理260亿美元的投资组合。Nanda先生持有印度特许会计师协会（Institute of Chartered Accountants）的特许会计。
- Ashish Nanda has served as a director since his appointment on February 22 2017. Since 1998 Mr. Nanda has been the Managing Director of Innovations Group, one of the largest outsourcing companies in the financial sector that employs close to 14000 people working across various financial sectors. Since 1992 Mr. Nanda has served as the Managing Partner of Capstone Insurance Brokers LLC and, since 2009 has served as Managing Partner of Dive Tech Marine Engineering Services L.L.C. From 1991 to 1994 Mr. Nanda held the position of Asst. Manager Corporate Banking at Emirates Banking Group where he was involved in establishing relationships with business houses owned by United Arab Emirates nationals and expatriates in order to set up banking limits and also where he managed portfolios of $26 billion. Mr. Nanda holds a Chartered Accountancy from the Institute of Chartered Accountants from India.
- Mario Philips
-
Mario Philips自2010年3月起担任LifeSciences高级副总裁和总经理。Philips于1999年11月加入ATMI，正值ATMI收购MST Analytics, Inc.，并担任ATMI Analytical Systems欧洲销售经理。2000年10月到2003年8月担任ATMI Packaging全球销售和市场经理；2003年8月到2004年8月担任ATMI Packaging固体包装业务总经理。Philips于2004年8月到2010年3月担任ATMI LifeSciences总经理。
Mario Philips has served as a director since his appointment on January 9 2020. Since March 2019 Mr. Philips has been Chief Executive Officer of PolyNeuroS, a drug company based in France that has developed a diagnostic platform technology for neurodegenerative diseases in combination with a therapy to cure neurodegenerative diseases such as ALS and Parkinson’s. Mr. Philips also acts as strategic partner for the private equity fund, Archimed, and has been the Chairman of the Board for its portfolio company, Clean Biologics since July 2019.Prior to that Mr. Philips acted as VP/GM for Danaher Pall Biotech business with full P&L responsibility for a $1.3 billion business unit. Mr. Philips joined Pall in February 2014 as part of the Pall acquisition of ATMI Life Sciences, and was appointed to Vice President and General Manager to lead the Single-Use Technologies BU. In this role he was responsible for leading and executing an aggressive investment and growth strategy.Mr. Philips joined ATMI in 1999 with ATMI’s acquisition of MST Analytics, Inc., serving as European Sales Manager for ATMI Analytical Systems. In 2004 Mr. Philips was appointed to General Manager of ATMI Packaging, a role he held through 2010 when he was promoted to the position of Senior Vice President and General Manager, ATMI Life Sciences. In that role, he was responsible for developing and executing all business strategies, including the introduction of new products and service solutions for the Life Sciences industry. A strong leading innovative IP portfolio was created, Pall acquired the business in 2014.Mr. Philips also held in the past several board member positions in the life sciences industry with Austar Life Sciences China, Disposable Lab (France) and Artelis (Belgium). - Mario Philips自2010年3月起担任LifeSciences高级副总裁和总经理。Philips于1999年11月加入ATMI，正值ATMI收购MST Analytics, Inc.，并担任ATMI Analytical Systems欧洲销售经理。2000年10月到2003年8月担任ATMI Packaging全球销售和市场经理；2003年8月到2004年8月担任ATMI Packaging固体包装业务总经理。Philips于2004年8月到2010年3月担任ATMI LifeSciences总经理。
- Mario Philips has served as a director since his appointment on January 9 2020. Since March 2019 Mr. Philips has been Chief Executive Officer of PolyNeuroS, a drug company based in France that has developed a diagnostic platform technology for neurodegenerative diseases in combination with a therapy to cure neurodegenerative diseases such as ALS and Parkinson’s. Mr. Philips also acts as strategic partner for the private equity fund, Archimed, and has been the Chairman of the Board for its portfolio company, Clean Biologics since July 2019.Prior to that Mr. Philips acted as VP/GM for Danaher Pall Biotech business with full P&L responsibility for a $1.3 billion business unit. Mr. Philips joined Pall in February 2014 as part of the Pall acquisition of ATMI Life Sciences, and was appointed to Vice President and General Manager to lead the Single-Use Technologies BU. In this role he was responsible for leading and executing an aggressive investment and growth strategy.Mr. Philips joined ATMI in 1999 with ATMI’s acquisition of MST Analytics, Inc., serving as European Sales Manager for ATMI Analytical Systems. In 2004 Mr. Philips was appointed to General Manager of ATMI Packaging, a role he held through 2010 when he was promoted to the position of Senior Vice President and General Manager, ATMI Life Sciences. In that role, he was responsible for developing and executing all business strategies, including the introduction of new products and service solutions for the Life Sciences industry. A strong leading innovative IP portfolio was created, Pall acquired the business in 2014.Mr. Philips also held in the past several board member positions in the life sciences industry with Austar Life Sciences China, Disposable Lab (France) and Artelis (Belgium).
- David Sidransky
-
David Sidransky博士，目前担任约翰·霍普金斯大学头颈部癌症研究部主任、耳鼻喉科—头颈部外科教授、细胞与分子医学教授以及泌尿科及遗传学教授。Sidransky博士目前亦担任约翰霍普金斯肿瘤中心的肿瘤科教授。从1984年至1988年，Sidransky博士在美国贝勒大学医学院工作，并取得其医学博士学位，随后继续担任内科实习生及驻院医生，及担任内科首席驻院医生直至1988年6月。从1988年7月至1992年6月，Sidransky博士在约翰·霍普金斯大学及医院完成肿瘤科研究生课程，随后于1992年7月获委任为教师。Sidransky博士于1981年6月毕业于美国布兰迪斯大学，获得化学理学士学位。Sidransky博士是美国癌症研究协会及美国临床肿瘤学协会的现任会员。彼曾为美国国家癌症研究所下属多个工作组（包括发展诊断工作组及癌症预防及控制工作组）的成员。Sidransky博士亦获得美国内科医学委员会及美国肿瘤医学委员会的认证。此外，Sidransky博士目前参与美国国家癌症研究所国家科学顾问委员会。彼为Champions Oncology, Inc.（纳斯达克：CSBR）的创始人，目前为董事会领导。彼为Galmed Pharmaceuticals Ltd.（纳斯达克：GLMD）董事、Orgenesis Inc.（纳斯达克：ORGS）董事、Advaxis, Inc.（纳斯达克：ADXS）主席及Ayala Pharmaceuticals, Inc.（纳斯达克：AYLA）主席。彼亦为空服员医学研究基金会（Flight Attendants Medical Research Foundation）及囊癌研究（Adenocystic Carcinoma Research）的MAB主席。Sidransky博士获得了许多荣誉，如以色列癌症研究基金奥瑟曼奖（Israel Cancer Research Fund Osserman Award）、AACR — Richardand Hinda Rosenthal Foundation Award、巴伊兰大学杜比高密奖（Toby Comet Award Bar Ilan University）及AACR Team Award Theme Circulating DNA。截至本公告日期，彼于专业期刊上曾发表逾550篇文章、撰写45篇书籍章节、评述及评论以及为28项专利的发明者。于2021年3月31日获委任为亚盛医药集团独立非执行董事。
David Sidransky,has served as Lead Director of the Company since November 2016. Previously, Dr. Sidransky served as the Chairman of the Company from October 2007 to November 2016 and has served as a director of the Company since August 2007. Dr. Sidransky is a Professor of Oncology, Otolaryngology-Head and Neck Surgery, Cellular & Molecular Medicine, Urology, Genetics, and Pathology at Johns Hopkins University and Hospital. In the field of oncology, Dr. Sidransky is one of the most highly-cited researchers in clinical and medical journals in the world, with over 600 peer-reviewed publications in the past decade. He has also contributed to more than 60 cancer reviews and chapters. Dr. Sidransky is a founder of a number of biotechnology companies and holds numerous biotechnology patents. He has served as Vice Chairman of the Board of Directors of ImClone Systems, Inc., a global biopharmaceutical company committed to advancing oncology care, and was a director, until its merger with Eli Lilly. Dr. Sidransky is Chairman of the Board of Ayala Pharmaceuticals and Advaxis Immunotherapies and serves on the board of directors of Galmed, Ascentage, and Orgenesis. From 2005 to 2008, Dr. Sidransky served as Director of the American Association for Cancer Research (AACR). Dr. Sidransky is the recipient of many awards and honors, including the 1997 Sarstedt International Prize from the German Society of Clinical Chemistry, the 1998 Alton Ochsner Award Relating Smoking and Health by the American College of Chest Physicians, the 2004 Hinda and Richard Rosenthal Award for innovative research and the 2017 team award from the AACR for the development of circulating DNA testing. Dr. Sidransky is certified in Internal Medicine and Medical Oncology by the American Board of Medicine. Dr. Sidransky received his bachelor's degree from Brandeis University and his medical degree from the Baylor College of Medicine. - David Sidransky博士，目前担任约翰·霍普金斯大学头颈部癌症研究部主任、耳鼻喉科—头颈部外科教授、细胞与分子医学教授以及泌尿科及遗传学教授。Sidransky博士目前亦担任约翰霍普金斯肿瘤中心的肿瘤科教授。从1984年至1988年，Sidransky博士在美国贝勒大学医学院工作，并取得其医学博士学位，随后继续担任内科实习生及驻院医生，及担任内科首席驻院医生直至1988年6月。从1988年7月至1992年6月，Sidransky博士在约翰·霍普金斯大学及医院完成肿瘤科研究生课程，随后于1992年7月获委任为教师。Sidransky博士于1981年6月毕业于美国布兰迪斯大学，获得化学理学士学位。Sidransky博士是美国癌症研究协会及美国临床肿瘤学协会的现任会员。彼曾为美国国家癌症研究所下属多个工作组（包括发展诊断工作组及癌症预防及控制工作组）的成员。Sidransky博士亦获得美国内科医学委员会及美国肿瘤医学委员会的认证。此外，Sidransky博士目前参与美国国家癌症研究所国家科学顾问委员会。彼为Champions Oncology, Inc.（纳斯达克：CSBR）的创始人，目前为董事会领导。彼为Galmed Pharmaceuticals Ltd.（纳斯达克：GLMD）董事、Orgenesis Inc.（纳斯达克：ORGS）董事、Advaxis, Inc.（纳斯达克：ADXS）主席及Ayala Pharmaceuticals, Inc.（纳斯达克：AYLA）主席。彼亦为空服员医学研究基金会（Flight Attendants Medical Research Foundation）及囊癌研究（Adenocystic Carcinoma Research）的MAB主席。Sidransky博士获得了许多荣誉，如以色列癌症研究基金奥瑟曼奖（Israel Cancer Research Fund Osserman Award）、AACR — Richardand Hinda Rosenthal Foundation Award、巴伊兰大学杜比高密奖（Toby Comet Award Bar Ilan University）及AACR Team Award Theme Circulating DNA。截至本公告日期，彼于专业期刊上曾发表逾550篇文章、撰写45篇书籍章节、评述及评论以及为28项专利的发明者。于2021年3月31日获委任为亚盛医药集团独立非执行董事。
- David Sidransky,has served as Lead Director of the Company since November 2016. Previously, Dr. Sidransky served as the Chairman of the Company from October 2007 to November 2016 and has served as a director of the Company since August 2007. Dr. Sidransky is a Professor of Oncology, Otolaryngology-Head and Neck Surgery, Cellular & Molecular Medicine, Urology, Genetics, and Pathology at Johns Hopkins University and Hospital. In the field of oncology, Dr. Sidransky is one of the most highly-cited researchers in clinical and medical journals in the world, with over 600 peer-reviewed publications in the past decade. He has also contributed to more than 60 cancer reviews and chapters. Dr. Sidransky is a founder of a number of biotechnology companies and holds numerous biotechnology patents. He has served as Vice Chairman of the Board of Directors of ImClone Systems, Inc., a global biopharmaceutical company committed to advancing oncology care, and was a director, until its merger with Eli Lilly. Dr. Sidransky is Chairman of the Board of Ayala Pharmaceuticals and Advaxis Immunotherapies and serves on the board of directors of Galmed, Ascentage, and Orgenesis. From 2005 to 2008, Dr. Sidransky served as Director of the American Association for Cancer Research (AACR). Dr. Sidransky is the recipient of many awards and honors, including the 1997 Sarstedt International Prize from the German Society of Clinical Chemistry, the 1998 Alton Ochsner Award Relating Smoking and Health by the American College of Chest Physicians, the 2004 Hinda and Richard Rosenthal Award for innovative research and the 2017 team award from the AACR for the development of circulating DNA testing. Dr. Sidransky is certified in Internal Medicine and Medical Oncology by the American Board of Medicine. Dr. Sidransky received his bachelor's degree from Brandeis University and his medical degree from the Baylor College of Medicine.
高管简历
中英对照 | 中文 | 英文- Vered Caplan
Vered Caplan自2014年8月14日以来一直担任我们的首席执行官兼董事会主席，在此之前，她从2013年12月23日开始担任临时总裁兼首席执行官。她于2012年2月加入我们的董事会。Caplan女士拥有硕士学位。Tel Aviv University生物医学工程专业信号处理；Tel Aviv University商业开发专业工程师管理；Technion-Israel Institute of Technology机械工程专业软件和CAD系统。
Vered Caplan has served as Orgenesis Inc.'s Chief Executive Officer "CEO" and Chairperson of the Board of Directors since August 14 2014 prior to which she served as Interim President and CEO commencing on December 23 2013. She joined Orgenesis Inc.'s Board of Directors in February 2012. Ms. Caplan holds a M.Sc. in biomedical engineering from Tel Aviv University specializing in signal processing; management for engineers from Tel Aviv University specializing in business development; and a B.Sc. in mechanical engineering from the Technion- Israel Institute of Technology specialized in software and cad systems.- Vered Caplan自2014年8月14日以来一直担任我们的首席执行官兼董事会主席，在此之前，她从2013年12月23日开始担任临时总裁兼首席执行官。她于2012年2月加入我们的董事会。Caplan女士拥有硕士学位。Tel Aviv University生物医学工程专业信号处理；Tel Aviv University商业开发专业工程师管理；Technion-Israel Institute of Technology机械工程专业软件和CAD系统。
- Vered Caplan has served as Orgenesis Inc.'s Chief Executive Officer "CEO" and Chairperson of the Board of Directors since August 14 2014 prior to which she served as Interim President and CEO commencing on December 23 2013. She joined Orgenesis Inc.'s Board of Directors in February 2012. Ms. Caplan holds a M.Sc. in biomedical engineering from Tel Aviv University specializing in signal processing; management for engineers from Tel Aviv University specializing in business development; and a B.Sc. in mechanical engineering from the Technion- Israel Institute of Technology specialized in software and cad systems.
- Neil Reithinger
Neil Reithinger于2014年8月1日被任命为首席财务官、秘书兼财务主管。Reithinger先生是Eventus Advisory Group有限责任公司（Eventus Advisory Group，LLC）的创始人兼总裁，该公司是一家在亚利桑那州注册成立的私人首席财务官服务公司，专门从事公开交易和新兴成长型公司的资本咨询和SEC合规。他也是Eventus Consulting，P.C.（亚利桑那州注册会计师事务所）的总裁。在成立Eventus之前，Reithinger先生从2009年3月到2009年12月担任New Leaf Brands，Inc.的首席运营官兼首席财务官，该公司是一家品牌饮料公司，营养专业首席执行官，Inc.从2007年4月到2009年10月是一家全国分布式营养补充剂公司，于1998年1月至2009年3月被Baywood International，Inc.的董事长，首席执行官，总裁兼董事Nutraceutical International，Inc.收购，Baywood International是一家上市营养补充剂公司和财务总监，Inc.从1994年12月到1998年1月。Reithinger先生在亚利桑那大学（University of Arizona）获得会计学学士学位，并且是一名注册会计师。他是美国注册会计师协会和亚利桑那州注册会计师协会（Arizona Society of Certified Public Accountants）的成员。
Neil Reithinger was appointed Chief Financial Officer, Secretary and Treasurer on August 1 2014. Mr. Reithinger is the Founder and President of Eventus Advisory Group, LLC, a private, CFO-services firm incorporated in Arizona, which specializes in capital advisory and SEC compliance for publicly-traded and emerging growth companies. He is also the President of Eventus Consulting, P.C., a registered CPA firm in Arizona. Prior to forming Eventus, Mr. Reithinger was Chief Operating Officer & CFO from March 2009 to December 2009 of New Leaf Brands, Inc., a branded beverage company, CEO of Nutritional Specialties, Inc. from April 2007 to October 2009 a nationally distributed nutritional supplement company that was acquired by Nutraceutical International, Inc., Chairman, CEO, President and director of Baywood International, Inc. from January 1998 to March 2009 a publicly-traded nutraceutical company and Controller of Baywood International, Inc. from December 1994 to January 1998. Mr. Reithinger earned a B.S. in Accounting from the University of Arizona and is a Certified Public Accountant. He is a Member of the American Institute of Certified Public Accountants and the Arizona Society of Certified Public Accountants.- Neil Reithinger于2014年8月1日被任命为首席财务官、秘书兼财务主管。Reithinger先生是Eventus Advisory Group有限责任公司（Eventus Advisory Group，LLC）的创始人兼总裁，该公司是一家在亚利桑那州注册成立的私人首席财务官服务公司，专门从事公开交易和新兴成长型公司的资本咨询和SEC合规。他也是Eventus Consulting，P.C.（亚利桑那州注册会计师事务所）的总裁。在成立Eventus之前，Reithinger先生从2009年3月到2009年12月担任New Leaf Brands，Inc.的首席运营官兼首席财务官，该公司是一家品牌饮料公司，营养专业首席执行官，Inc.从2007年4月到2009年10月是一家全国分布式营养补充剂公司，于1998年1月至2009年3月被Baywood International，Inc.的董事长，首席执行官，总裁兼董事Nutraceutical International，Inc.收购，Baywood International是一家上市营养补充剂公司和财务总监，Inc.从1994年12月到1998年1月。Reithinger先生在亚利桑那大学（University of Arizona）获得会计学学士学位，并且是一名注册会计师。他是美国注册会计师协会和亚利桑那州注册会计师协会（Arizona Society of Certified Public Accountants）的成员。
- Neil Reithinger was appointed Chief Financial Officer, Secretary and Treasurer on August 1 2014. Mr. Reithinger is the Founder and President of Eventus Advisory Group, LLC, a private, CFO-services firm incorporated in Arizona, which specializes in capital advisory and SEC compliance for publicly-traded and emerging growth companies. He is also the President of Eventus Consulting, P.C., a registered CPA firm in Arizona. Prior to forming Eventus, Mr. Reithinger was Chief Operating Officer & CFO from March 2009 to December 2009 of New Leaf Brands, Inc., a branded beverage company, CEO of Nutritional Specialties, Inc. from April 2007 to October 2009 a nationally distributed nutritional supplement company that was acquired by Nutraceutical International, Inc., Chairman, CEO, President and director of Baywood International, Inc. from January 1998 to March 2009 a publicly-traded nutraceutical company and Controller of Baywood International, Inc. from December 1994 to January 1998. Mr. Reithinger earned a B.S. in Accounting from the University of Arizona and is a Certified Public Accountant. He is a Member of the American Institute of Certified Public Accountants and the Arizona Society of Certified Public Accountants.
- Efrat Assa Kunik
Efrat Assa Kunik于2021年12月被任命为首席发展官。Assa-Kunik博士于2016年9月加入公司，担任临床前开发主管。2017年8月，她被任命为以色列子公司总经理。Assa-Kunik博士在魏茨曼科学研究所获得遗传学和发育生物学领域的博士学位，并在本-古里安大学获得免疫学和癌症研究硕士学位。此外，Assa-Kunik博士是魏茨曼研究所神经生物学系的博士后。在完成博士后研究后，Assa-Kunik博士作为高级科学家加入了BioGenCell。2012年，她加入Pharmaseed公司，担任业务发展部门主管、业务发展副总裁和美国业务发展活动经理。
Efrat Assa Kunik was appointed Chief Development Officer in December 2021. Dr. Assa-Kunik joined the Company in September 2016 as Head of Pre-Clinical Development. In August 2017 she was appointed General Manager of the Israeli subsidiary. Dr Assa-Kunik earned her PhD at the Weizmann Institute of Science in the fields of genetics and developmental biology and a Masters from the Ben-Gurion University in immunology and cancer research. Additionally, Dr Assa-Kunik was a postdoctoral fellow at the Weizmann Institute in the department of neural biology. After completing her postdoc, Dr. Assa-Kunik joined BioGenCell as a Senior Scientist. In 2012 she joined Pharmaseed as the director of the Business Development Unit, VP business development and manager of the business development activity in USA.- Efrat Assa Kunik于2021年12月被任命为首席发展官。Assa-Kunik博士于2016年9月加入公司，担任临床前开发主管。2017年8月，她被任命为以色列子公司总经理。Assa-Kunik博士在魏茨曼科学研究所获得遗传学和发育生物学领域的博士学位，并在本-古里安大学获得免疫学和癌症研究硕士学位。此外，Assa-Kunik博士是魏茨曼研究所神经生物学系的博士后。在完成博士后研究后，Assa-Kunik博士作为高级科学家加入了BioGenCell。2012年，她加入Pharmaseed公司，担任业务发展部门主管、业务发展副总裁和美国业务发展活动经理。
- Efrat Assa Kunik was appointed Chief Development Officer in December 2021. Dr. Assa-Kunik joined the Company in September 2016 as Head of Pre-Clinical Development. In August 2017 she was appointed General Manager of the Israeli subsidiary. Dr Assa-Kunik earned her PhD at the Weizmann Institute of Science in the fields of genetics and developmental biology and a Masters from the Ben-Gurion University in immunology and cancer research. Additionally, Dr Assa-Kunik was a postdoctoral fellow at the Weizmann Institute in the department of neural biology. After completing her postdoc, Dr. Assa-Kunik joined BioGenCell as a Senior Scientist. In 2012 she joined Pharmaseed as the director of the Business Development Unit, VP business development and manager of the business development activity in USA.